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INTRODUCTION
The field of infectious diseases is enjoying a renaissance in professional and popular media. This inter-st derives primarily from three concerns: bioterrorism, antibiotic resistance, and emerging infectious
diseases. In this article we only discuss the last of these; however, it is important to recognize that the pub-
lic health infrastructure required to address each is similar. The 1999 outbreak of West Nile virus infec-
tions in New York City captured attention beyond its immediate clinical significance because it exposed
U.S. vulnerability to exotic infectious agents and demonstrated the importance of investment in public health
systems and methods for rapid characterization of and response to novel agents.
West Nile virus is a member of the Japanese encephalitis antigenic complex within the family Flaviviridae,
genus Flavivirus (10,34). Other pathogens within this complex include Alfuy, Cacipacore, Koutango, Japan-
ese encephalitis, Kunjin, Murray Valley encephalitis, St. Louis encephalitis, Usutu, and Yaounde viruses(34). West Nile virus is primarily arthropod-borne; mosquitoes are the primary vector for transmission
among vertebrate hosts. The name West Nile virus derives from its initial isolation in the West Nile dis-
trict of Uganda from the blood of a febrile patient in 1937 (83). The first epidemics of West Nile fever
were documented in Israel in the early 1950s (46,51). The largest epidemic reported occurred in South
Africa in 1974 after unusual heavy rainfalls and resulted in thousands of hospital admissions (54). Out-
breaks of human West Nile virus infection have been reported throughout the Middle East, Sub-Saharan
Africa, Europe, Asia (reviewed by Hubálek and Halouzka [37]), and, recently, in the New York City area
of North America (3-5,8,24,48,86). There is consensus that West Nile virus outbreaks are increasing in fre-
quency and geographic distribution. Serologie analysis of banked specimens indicates that West Nile virus
is likely to have been newly introduced to North America in 1999; however, the extent to which enhanced
awareness contributes to increased case ascertainment in other geographic areas is less clear. Factors pro-
posed to contribute to West Nile virus emergence are similar to those described for many other infectious
diseases: increased international travel and trade, human incursion into wildlife habitats, and changes in
host and vector density and activity (61,78).
The most common clinical presentation of West Nile virus infection is fever associated with headache,
myalgias, lymphadenopathy and maculopapular rash (30,51). Meningoencephalitis is less frequent, may be
fatal, and typically occurs in elderly or immunosuppressed individuals (85). Rarely, meningoencephalitis
occurs in healthy young adults and children (26). The youngest individual with severe meningoencephali-
tis during the 1999 New York City outbreak was an otherwise healthy 16-year-old. Human infection can
also result in myocarditis (2) and pancreatitis (69); however, these complications may be more common in
equine and avian hosts. Treatment for West Nile virus infection is supportive; specific antiviral chemother-
apy is not available.
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In areas in Egypt where West Nile virus is endemic, exposure typically occurs early in childhood and up
to 90% of adults have sérologie evidence of previous infection (19,91). The northern Queens serosurvey
after the 1999 New York City outbreak indicated an exposure rate of 1.2% to 4.1%; 62 patients had severe
central nervous system (CNS) disease, of which seven cases were fatal (43).
Infection is transmitted chiefly by mosquitoes, although a role for ticks and other hematophagous insects
cannot be excluded (37,40,64,91). The ecology of transmission between mosquito vectors and vertebrate
hosts is complex. Although many species are competent to carry West Nile virus, feeding preferences dif-
fer, as do the geographic distributions of various species. Thus, a mosquito must feed on an infected am-
plifying host, likely a bird, to serve as an effective vector. The mosquito genus Culex is implicated most
commonly worldwide (37,91), and is postulated to have been the major vector in the New York City out-
break (3,17,25). Infected Aedes mosquitoes may also serve as transmission vectors. Birds have sustained
high level viremia and are likely to be the most important vertebrate reservoirs for West Nile virus ampli-
fication and transmission (37,55,91,92). Bird migration provides a potential basis for viral transport over
large distances and has been proposed as an explanation for the seasonal recurrence of West Nile virus in-
fections in temperate zones where winter precludes mosquito activity (77). However, transovarial trans-
mission of virus and overwintering has been demonstrated in mosquitoes. The extent to which these two
mechanisms contribute to the epidemiology of West Nile virus infection is unknown.
Infection with West Nile virus is diagnosed by virus isolation, serology, and reverse transcription-poly-
merase chain reaction (RT-PCR) (4,7,8,23,28-30,44,54,68,70,71,84). Cross-reactivity between members of
the Japanese encephalitis antigenic complex can confound sérologie analysis; however, specific im-
munoglobulin M (IgM) capture enzyme-linked immunosorbent assay (ELISA) and neutralization tests have
been established (60). Virus is readily cultivated from birds, mosquitoes, and occasionally, horses. Virus
load is lower in humans and thus virus isolation may be more difficult. Infectious virus was not isolated
from human victims of the 1999 New York City outbreak.
Two genetic lineages are established based on signature motifs in envelope gene sequence (6). Whereas
lineage I viruses are associated with outbreaks of acute human disease, lineage II viruses appear to be con-
fined to endemic, enzootic cycles. Flavivirases infect permissive cells by receptor-mediated endocytosis.
Different patterns in neuroinvasiveness and neurovirulence of flavivirases are typically associated with
changes in envelope protein sequence and occasionally with mutations in the nonstractural region (13,57).
St. Louis encephalitis and Murray valley encephalitis viruses have been reported to gain entry into the brain
by migration along olfactory neurons (58,59). Virus is proposed to infect the olfactory neuroepithelium via
blood capillaries during the viremic phase.
WEST NILE VIRUS IN NEW YORK CITY
In late August 1999, health officials reported an outbreak of encephalitis accompanied by profound mus-
cle weakness and axonal neuropathy in the borough of Queens, New York City (4,5). There was no ap-
parent overall increase in the frequency in New York of encephalitis per se that resulted in detection of the
outbreak. Thus, the initial recognition of the syndrome must be credited to the clinical acumen of Dr. Deb-
orah Asnis, an infectious diseases physician at Flushing Hospital Medical Center, Dr. Marcelle Layton, As-
sistant Commissioner, Communicable Disease Program New York City Department of Health, and their as-
sociates.
On September 3, sérologie analysis (IgM capture ELISA) for the presence of antibodies to North Amer-
ican arboviruses by the Division of Vector Borne Infectious Diseases of the Centers for Disease Control
and Prevention (CDC) in Fort Collins, Colorado, yielded results not inconsistent with infection with St.
Louis encephalitis (SLE) virus (4). SLE had not been previously reported in New York City but mosquito
vectors competent for transmission of SLE virus were present. Investigation of the outbreak epicenter in
northern Queens revealed sites of active mosquito breeding and early victims of the outbreak had histories
consistent with mosquito exposure. Thus, on September 3 a mosquito control program was jointly adopted
by the State and City of New York (4). Concurrently, wildlife observers independently noted increased mor-
tality of birds, including free-ranging crows and exotic birds housed in the Bronx Zoo. Dr. Tracy McNa-
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mara, a veterinary pathologist at the Wildlife Conservation Society, Bronx, New York, performed histo-
logie analyses of birds and found meningoencephalitis, gross hemorrhage of the brain, splenomegaly, and
myocarditis (86). On September 10 she forwarded tissue samples from diseased birds to the United States
Department of Agriculture (USDA) National Veterinary Service Laboratory in Ames, Iowa, where virus
was isolated and electron micrography was consistent with the presence of either a togaviras or a flavivirus.
Thereafter the avian virus was forwarded from the USDA to the CDC Fort Collins for molecular analysis
(48).
Incidentally, on September 13-15, the CDC Encephalitis Project (comprised of centers in California, New
York and Tennessee) held its annual meeting in Albany, New York. Data from both California and New
York over an 18-month survey period indicated that an etiological agent was never identified in 70% of
cases of encephalitis despite culture, serology, and molecular analyses. In this context, our group was in-
vited to discuss methods for identification of unknown pathogens and to consider application to project
samples of a new method for amplifying viral nucleic acids, domain-specific differential display (DSDD).
DSDD is a hybrid of consensus polymerase chain reaction (PCR) and differential display wherein highly
degenerate family-specific primers are used in PCR and resultant products analyzed by polyacrylamide elec-
trophoresis or by chromatography. Efforts to amplify SLE virus sequences by conventional RT-PCR from
brains of serologically confirmed human cases of SLE from the New York City outbreak were unsuccess-
ful in several laboratories. Thus, in an effort to circumvent limitations of conventional PCR and to test the
utility of the DSDD method we were given brain samples from five people who died during the New York
City outbreak.
Several degenerated primer sets were modified from sequences described by Chow et al. (15), Tanaka
(90), and Pierre et al. (70) corresponding to the NS3 serine protease/helicase domains and conserved se-
quence motifs in the NS5 gene and 3' untranslated region of flavivirases. Nested primers were located to-
wards the 5'-end of NS5 sequence, spanning conserved amino acid motifs AKGSRAIWXMWLGARXLE-
FEALGFLNXHW, DDTAGWDT, and QRGSGQVXTY (Fig. 1) (8).
Despite postmortem autolysis to the extent that 28S ribosomal RNA was not visible in ethidium bromide-
stained agarose gels, flavivirus sequences were obtained from 4 of the 5 brain samples on September 22.
Amplification products from two of these subjects (Fig. 1 ; sequenced amplification products are indicated
by boxes) were virtually identical and demonstrated the presence of a virus more similar to Kunjin virus
strain MRM61c, an Australasian lineage I West Nile virus, and West Nile virus strain Wengler, a Nigerian
lineage II virus, than to St. Louis encephalitis virus (Table 1) (8). Concurrently, our colleagues at the CDC
in Fort Collins reported West Nile virus-like sequences in cell lines infected with homogenates from New
York birds (4). In concert these findings confirmed that the outbreak in New York City was a zoonosis due
to West Nile virus.
In the weeks that followed, our use of the term "Kunjin/West Nile-like" virus for the New York isolate
generated considerable controversy (24). Although the Australasian Kunjin virus has historically been con-
sidered similar to but different from the African and Eurasian West Nile virus, it has recently been reclas-
sified as a subtype of West Nile virus (34). In retrospect, the similarity of West Nile virus New York 1999
820/900 bp
670/750 bp
5' prM NS1 NS2A/B NS3 NS4A/B NS5 3'
470 bp 370 bp 170 bp
FIG. 1. Positions of primers used for the detection of West Nile virus NY1999. The amplification products indi-
cated by boxes were sequenced directly without subcloning.
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Table 1. Sequence Analysis of Amplification Products from the New York 1999 Virus (Patient #1)
Percent identity to NY 1999*
MRMólc Wengler St. Louis
Region NT AA NT AA NT AA
NS3 (470 bp) 88 98 82 94 ÑAS NAS
NS5 (370 bp) 87 99 80 95 70 76
NS5 (170 bp) 88 100 80 96 80 89
"Percent identity of nucleotide (NT) and deduced amino acid (AA) sequence between the three amplified regions of the
New York isolate and Kunjin MRMólc, West Nile Wengler, and St. Louis encephalitis MSI.7 viruses; the two fully
sequenced West Nile virus genomes and the partial St. Louis encephalitis virus genome available at the time.
NAS, no available sequence.
(NY 1999) from human brain to the MRM61c isolate was significant in that it allowed early and accurate
recognition of the New York isolate as a lineage I West Nile virus, viruses associated with outbreaks of
acute disease.
CHARACTERIZATION OF WEST NILE VIRUS NY1999
To investigate a possible origin of West Nile virus NY 1999, we cloned its genome from postmortem hu-
man brain by RT-PCR. RNA integrity was suboptimal; thus, 17 overlapping amplification products were
required to assemble a genomic sequence comprising 10,945 nucleotides (41).
The flaviviral envelope (E) protein, encoded by the E gene, is the major target of humoral immune re-
sponses, and has a central role in West Nile virus taxonomy. Subtypes of West Nile virus are distinguished
by antigenic variations in the E protein (1,18,27,33,80). Two genotypic lineages of West Nile virus are pro-
posed based on specific signature amino acid motifs as well as on the presence or absence of a 12 nucleotide
deletion that includes coding sequence for an N-glycosylation site (Asn-Tyr-Ser) at amino acid positions
154-156 (6,80). Lineage I includes West Nile and Kunjin viruses from Europe, the Middle East, and north,
central and west Africa, and Australasia. Lineage II includes West Nile virus isolates from west, central,
and east Africa, and from Madagascar. Analysis of deduced E protein sequence of West Nile virus NY 1999
revealed integrity of the N-glycosylation site and the presence of signature amino acid motifs Ala 172,
Asnl99, Thr205, Thr208, and Thr210, characteristic of lineage I viruses (41). Phylogenetic analysis of West
Nile virus NY 1999 E region sequence in relation to other West Nile viruses including Kunjin virus also in-
dicated membership in lineage I (Fig. 2). Assignment of phylogenetic relationship based on short pieces of
sequence (<300 nt) from a single genome region may be misleading (47,80). Therefore, we extended our
analysis to additional regions for which sequence information was available for other West Nile virus iso-
lates. Analysis of 3' untranslated regions indicated that the West Nile virus NY 1999 sequence was most
closely related to West Nile virus isolates that had previously been assigned to lineage I based on E gene
sequence (Fig. 2). Similarly, phylogenetic analysis of NS3 and NS5 sequences also demonstrated two lin-
eages placing West Nile virus NY1999 with lineage I isolates, not with lineage II isolates (41).
The closest match found was with an isolate obtained in 1998 in Israel (Israel-98). In fact, sequences of
West Nile viruses NY 1999 and Israel-98 were identical for the 227 nucleotides of E gene sequence avail-
able for our analysis (41). Only two mismatches were found in an analysis of a 1278 nucleotide long prM/E
sequence, and this high degree of similarity between these two isolates prompted conjecture concerning an
Israeli origin of West Nile virus NY1999 (48). It is conceivable that West Nile virus NY1999 arrived in
North America through importation of an infected bird or mosquito from Israel; current knowledge sug-
gests that viremia in an infected human travelling to New York from an endemic area may be too low to
transfer virus to mosquitoes to initiate an epidemic cycle. Enhanced surveillance in Israel resulted in de-
tection of West Nile virus infection in domestic goslings in Yizre'el and Ramala districts and destruction
of 8,000 birds (74).
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FIG. 2. Phylogenetic analysis of West Nile virus NY1999 envelope and 3' untranslated region.
ESTABLISHMENT OF MOLECULAR ASSAYS FOR DIAGNOSIS OF WEST NILE
VIRUS INFECTION
In early October 1999 in response to requests from several State Departments of Health (New York, Con-
necticut, Vermont, Florida, California) we posted primer and protocols for RT-PCR detection of West Nile
virus NY1999 on ProMED-mail (75). Rapid implementation of this method demonstrated the significance
of electronic media in dissemination of diagnostic reagents in outbreak situations. Thereafter, to facilitate
high throughput, rapid, and sensitive molecular detection and clinical microbiology of West Nile virus
NY1999, we established a real-time 5'-nuclease RT-PCR method (7).
Real-time 5'-nuclease PCR is a method in which the presence of a target sequence is detected through
continuous measurement of a fluorescent dye label that is generated by nuclease digestion of a labeled probe
oligonucleotide during the course amplification (35,36,49,50). Though nested PCR is similar in sensitivity
to real-time PCR, the latter is quantitative over a wide dynamic range, readily adapted to high throughput
in a clinical laboratory, and less sensitive to false positive results because assays are performed in a closed
system. We established a reverse transcription real-time 5'-nuclease PCR assay for West Nile virus NY 1999
using an ABI Prism 7700 Sequence Detector and two primer/fluorescent-probe sets targeting genome re-
gions in the NS3 and NS5 genes (7). The sensitivity of the assays for detection of NS3 or NS5 sequences
was determined to be 50-100 molecules using synthetic RNA transcripts corresponding to the respective
regions of the West Nile virus NY1999 genome (GenBank Ace. No. AF202541). A linear dynamic range
of more than five orders of magnitude was determined using virus tissue culture seed, and specificity for
West Nile virus NY 1999 was confirmed using NS3 and NS5 sequences of St. Louis encephalitis virus, the
other flavivirus of the Japanese encephalitis antigenic complex associated with human disease in North
America.
We obtained 18 coded cerebrospinal fluid (CSF) specimens from the New York State Department of
Health for blinded analyses: 10 samples from subjects with serologically confirmed West Nile virus NY1999
infection, and 8 samples from subjects with neurologic disease not due to West Nile virus infection. Whereas
no West Nile virus sequences were detected in the 8 controls, all 6 samples from serologically confirmed
West Nile viras NY 1999 subjects with a fatal outcome were found positive (6 samples from 4 subjects in-
cluding 3 samples obtained at different time points from 1 subject; 6 positive for NS5, 5 positive for NS3)(7). One sample from one serologically confirmed West Nile virus NY 1999 subject with nonfatal outcome
was found positive for NS5 sequence; three samples from three serologically confirmed West Nile virus
NY 1999 subjects with nonfatal outcome were negative by PCR for either gene sequence. The one surviv-
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ing subject with detectable West Nile virus sequences in CSF was a 16-year-old male, the youngest patient
with severe disease reported during the outbreak (age of the other cases ranged from 54 to 87 years).
Real-time RT-PCR results can be obtained within hours and may facilitate selection of appropriate ther-
apy, although at this time no specific therapy directed against West Nile virus is available.
IDENTIFICATION OF WEST NILE VIRUS ANTIVIRAL COMPOUNDS
The finding that West Nile virus had persisted in mosquitoes in New York City over the winter season
1999-2000 (12,17) emphasizes the importance of rapidly identifying antiviral drags. To initiate antiviral
studies we tested a panel of nucleoside analogues for activity against West Nile virus NY1999 in human
oligodendrocytes (OL cell line; generated by Y. Iwasaki at the Wistar Institute, Philadelphia, PA, in the
1970s). Two compounds had antiviral activity, pyrazofurin and ribavirin (42). Sensitivity of West Nile virus
to pyrazofurin suggests that drags that impact activity of orotate monophosphate decarboxylase (9,67) in
pyrimidine biosynthesis may be useful; however, due to high cytotoxicity, this compound was not tested
further. Ribavirin is a guanosine analogue (76) with a broad spectrum of antiviral activities against DNA
and RNA viruses (38,45,81,82). Phosphorylated after entry into the host cell it inhibits some viral poly-
merases (11,22,93); interferes with host cell inosine monophosphate dehydrogenase, resulting in reduction
of the intracellular GTP pool (87); reduces translation efficiency of some viral RNAs (31); and at low con-
centrations can enhance the TH1 antiviral immune response (63,89). Ribavirin has been used for treatment
of respiratory syncytial virus infection (32,88), Lassa fever (52), Argentine hemorrhagic fever (21), hem-
orrhagic fever with renal syndrome caused by Hantaan virus (39), La Crosse encephalitis (56), and (in com-
bination with interferon-a) hepatitis C virus infection (20,53,72,79).
The effects of ribavirin on West Nile virus NY1999-induced cytopathic effect in the neural cell line, cel-
lular proliferation, and levels of extracellular viral RNA were assessed at various drug concentrations. Lev-
els of ribavirin above 50 pM reduced virus-induced cytopathic effect, extracellular viral RNA, and im-













FIG. 3. Effect of ribavirin on West Nile virus replication and pathogenesis in the neural OL cell line. Dosis-de-
pendent effect of ribavirin on virus-induced cytopathic effect (filled squares), infected host cell proliferation (filled cir-
cles), and extracellular viral RNA (filled triangles). Parallel controls in uninfected cells included quantitation of drag-
induced cytotoxicity and effect of ribavirin on cell proliferation (inset).
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observed in both noninfected and infected cells at levels above 400 pM of ribavirin. Viral titers were re-
duced by four orders of magnitude in the presence of 200 pM ribavirin (from 107 to less than 103 plaque
forming units per milliliter). Similar experiments were pursued in a nonneural primate cell line, African
green monkey kidney (Vero) cells. Higher concentrations of ribavirin were required for inhibition of virus-
induced cytopathic effect in Vero than in OL cells.
It is clearly important to identify drags against West Nile virus infection with better selectivity and ther-
apeutic indices than ribavirin. Furthermore the efficacy of ribavirin in animal models of West Nile virus
encephalitis remains to be addressed; a report from 1977 indicates that this drag can decrease mortality due
to West Nile virus infection in adult Swiss albino mice (66). There is only limited information available
about its efficacy against viral encephalitis in humans but ribavirin has been shown to penetrate into the
CNS after oral administration (16). In one case each of La Crosse encephalitis (56) and subacute measles
encephalitis (62), treatment with ribavirin was reported to improve prognosis. Ribavirin is highly effective
against La Crosse virus in vitro (11); because of weaker antiviral activity against West Nile virus the de-
sirable high therapeutic dosage of ribavirin will likely result in reversible hemolytic anemia that may re-
quire transfusion (14).
FUTURE DIRECTIONS
West Nile virus appears to have established its presence in North America and is likely to extend its
global range. At the time this review was submitted for publication in early August 2000 three human pa-
tients were reported infected with West Nile virus in North America in 2000 (65). West Nile virus-infected
birds were found in a wide area spanning the boroughs of Staten Island and Queens in New York City; as
well as several counties in New York, New Jersey, Massachusetts, and Connecticut (65). Positive mosquito
pools (Culex spp. andAedesjaponicus) were collected in New York, Connecticut, and Massachusetts (65,73).
Insecticide application has resumed in a politically charged atmosphere where pundits debate the relative
risks of infection and environmental toxicity. Targeted federal funding has allowed establishment of sur-
veillance networks throughout the eastern United States.
At the height of the 1999 outbreak only a fraction of encephalitis in the greater New York area could be
attributed to West Nile vims. National and regional encephalitis incidence data alone would not have revealed
the presence of an exotic agent. Recognition of West Nile virus was the result of converging observations
from astute physicians and veterinarians in clinical practice who engaged receptive epidemiologists. One les-
son therefore is that effective infectious disease surveillance and pathogen discovery require multidisciplinary
partnerships in comparative medicine. Another is that it is time to use new technologies and paradigms for in-
vestigating the vast majority of encephalitides in which infectious agents have not been detected.
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